HIGHLIGHTS
- who: September and collaborators from the Aichi Medical University, Japan have published the paper: Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial, in the Journal: (JOURNAL)
- what: In the present trial, the results showed that the cumulative effective rate (any criteria) was 70.3% at 4 weeks, indicating that avatrombopag is effective in increasing the platelet counts in patients with CIT.
SUMMARY
(Al-Samkari et_al, 2022). Chemotherapy-induced thrombocytopenia (CIT) is one of the most common complications of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.